Epigral has received approval to raise funds up to Rs 400 crore by way of issuance of non-convertible debentures (NCDs), bonds and/or other debt securities etc. through permissible mode within the borrowing limits of the company, in one or more tranches / series. The board of directors of the company in their meeting held on August 2, 2025, have approved the same.
Epigral is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products.
